KR102158948B1 - 약물 전달 시스템 - Google Patents

약물 전달 시스템 Download PDF

Info

Publication number
KR102158948B1
KR102158948B1 KR1020197018829A KR20197018829A KR102158948B1 KR 102158948 B1 KR102158948 B1 KR 102158948B1 KR 1020197018829 A KR1020197018829 A KR 1020197018829A KR 20197018829 A KR20197018829 A KR 20197018829A KR 102158948 B1 KR102158948 B1 KR 102158948B1
Authority
KR
South Korea
Prior art keywords
coating
testosterone
delete delete
drug delivery
delivery system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197018829A
Other languages
English (en)
Korean (ko)
Other versions
KR20190083369A (ko
Inventor
요하네스 마르티누스 마리아 블로에머스
안코 코넬루스 에이슨스
헨데릭 윌리엄 프리즈린크
레오나르뒤스 헤라르뒤스 요제프 델리드
Original Assignee
이비 아이피 하이브리탭스 비.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이비 아이피 하이브리탭스 비.브이. filed Critical 이비 아이피 하이브리탭스 비.브이.
Publication of KR20190083369A publication Critical patent/KR20190083369A/ko
Application granted granted Critical
Publication of KR102158948B1 publication Critical patent/KR102158948B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020197018829A 2011-05-13 2012-05-14 약물 전달 시스템 Active KR102158948B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP11166091.6 2011-05-13
EP11166091 2011-05-13
EP11181165 2011-09-13
EP11181165.9 2011-09-13
EP11183732 2011-10-03
EP11183732.4 2011-10-03
PCT/NL2012/050336 WO2012158030A2 (en) 2011-05-13 2012-05-14 Drug delivery system

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020137033031A Division KR20140048882A (ko) 2011-05-13 2012-05-14 약물 전달 시스템

Publications (2)

Publication Number Publication Date
KR20190083369A KR20190083369A (ko) 2019-07-11
KR102158948B1 true KR102158948B1 (ko) 2020-09-24

Family

ID=46197660

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197018829A Active KR102158948B1 (ko) 2011-05-13 2012-05-14 약물 전달 시스템
KR1020137033031A Ceased KR20140048882A (ko) 2011-05-13 2012-05-14 약물 전달 시스템

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020137033031A Ceased KR20140048882A (ko) 2011-05-13 2012-05-14 약물 전달 시스템

Country Status (15)

Country Link
US (4) US9763884B2 (enExample)
EP (1) EP2709597A2 (enExample)
JP (1) JP6121990B2 (enExample)
KR (2) KR102158948B1 (enExample)
CN (2) CN103648487B (enExample)
AU (1) AU2012256501B2 (enExample)
BR (1) BR112013029199B1 (enExample)
CA (1) CA2835845C (enExample)
EA (1) EA034288B1 (enExample)
IL (1) IL229425B (enExample)
MX (1) MX353623B (enExample)
PH (1) PH12013502325A1 (enExample)
SG (2) SG10201606751XA (enExample)
WO (1) WO2012158030A2 (enExample)
ZA (1) ZA201309156B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160095818A1 (en) * 2013-06-03 2016-04-07 Mcneil Ab Solid pharmaceutical dosage form for release of at least one active pharmaceutical ingredient in the oral cavity
US20160279146A1 (en) 2013-11-11 2016-09-29 Limoxifen B.V. Methods and pharmaceutical formulations for treatment of selective estrogen-receptor modulator-induced adverse drug reactions
EP3248592A1 (en) * 2016-05-25 2017-11-29 EB IP Hybritabs B.V. Process for the preparation of drug delivery systems having a testosterone compound present in an outer layer or part, as well as such drug delivery systems
AU2017445093B2 (en) * 2017-12-29 2024-09-19 Exentis Knowledge Gmbh Drug delivery system
US20190381056A1 (en) 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
KR102084602B1 (ko) * 2018-11-08 2020-03-04 주식회사 서흥 발포성 및 안정성이 향상된 구강 세정용 발포정
WO2024253526A1 (en) 2023-06-06 2024-12-12 Van Rooij Kim Compositions for treating a subject from sexual dysfunction
US20250073171A1 (en) * 2023-09-05 2025-03-06 Freya Pharma Solutions Holding B.V. Drug delivery system for the treatment of female sexual interest and arousal disorder

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110033506A1 (en) * 2008-02-08 2011-02-10 Adel Penhasi Combination dosage form of low-dose modafinil and low-dose sildenafil

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4877774A (en) * 1987-09-09 1989-10-31 The United States Of America As Represented By The Department Of Health And Human Services Administration of steroid hormones
US5120720A (en) * 1990-09-20 1992-06-09 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Preparation of lipophile:hydroxypropylcyclodextrin complexes by a method using co-solubilizers
US5162117A (en) 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition
AU3949093A (en) 1992-03-31 1993-11-08 Benzon Pharma A/S A pharmaceutical formulation
US5260069A (en) 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
US5547948A (en) * 1995-01-17 1996-08-20 American Home Products Corporation Controlled release of steroids from sugar coatings
US5698560A (en) 1995-03-01 1997-12-16 Kyowa Hakko Kogyo Co., Ltd. Imidazoquinazoline derivatives
US5840332A (en) 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
JP3134187B2 (ja) * 1996-03-07 2001-02-13 武田薬品工業株式会社 放出制御組成物
US6245351B1 (en) 1996-03-07 2001-06-12 Takeda Chemical Industries, Ltd. Controlled-release composition
AU5310898A (en) * 1996-12-20 1998-07-17 Dumex-Alpharma A/S Release-controlled coated tablets
US5788987A (en) 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
WO1999018938A1 (en) 1997-10-09 1999-04-22 Perio Products Ltd. Delayed total release gastrointestinal drug delivery system
IL141762A0 (en) * 1998-10-01 2002-03-10 Novartis Ag New oral formulations
US6977083B1 (en) * 1998-10-02 2005-12-20 Jenapharm Gmbh & Co. Kg Bioadhesive tablet containing testosterone/testosterone ester mixtures and method for producing a predetermined testosterone time-release profile with same
UA67802C2 (uk) 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
US6632451B2 (en) * 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
SE9902386D0 (sv) * 1999-06-22 1999-06-22 Astra Ab New formulation
US20030027804A1 (en) * 2001-06-27 2003-02-06 Van Der Hoop Roland Gerritsen Therapeutic combinations for the treatment of hormone deficiencies
CA2463687A1 (en) * 2001-10-18 2003-04-24 Decode Genetics Ehf Cyclodextrin complexes
AR045068A1 (es) * 2003-07-23 2005-10-12 Univ Missouri Formulacion de liberacion inmediata de composiciones farmaceuticas
US20050031688A1 (en) * 2003-08-04 2005-02-10 Ayala William J. Positive wakeup pharmaceutical sleep system with compatible pre-bedtime administration
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
CN1946376A (zh) * 2004-03-25 2007-04-11 布里斯托尔-迈尔斯·斯奎布公司 包衣片剂组合物及其制法
RS52945B (sr) 2004-05-11 2014-02-28 Emotional Brain B.V. Farmaceutske formulacije i njihova primena u lečenju ženske seksualne disfunkcije
WO2006027680A1 (en) 2004-09-10 2006-03-16 Pfizer Limited 3-(1-carbamoylcyclohexyl) propionic acid derivatives as inhibitors of neutral endopeptidase enzyme
CN101146521A (zh) * 2005-03-14 2008-03-19 太阳医药高级研究有限公司 提供包含纤维素和甲基丙烯酸衍生物包衣的口服药物输送系统
FR2883179B1 (fr) * 2005-03-18 2009-04-17 Ethypharm Sa Comprime enrobe
WO2007002823A2 (en) * 2005-06-29 2007-01-04 Wyeth Formulations of conjugated estrogens and bazedoxifene
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
CN100551373C (zh) 2005-12-01 2009-10-21 北京华素制药股份有限公司 盐酸丁螺环酮缓/控释微丸
WO2007106708A2 (en) 2006-03-10 2007-09-20 Novartis Ag Combinations of the angiotensin ii antagonist valsartan and the nep inhibitor daglutril
GB0606562D0 (en) 2006-03-31 2006-05-10 Novartis Ag Organic compounds
TW200806282A (en) * 2006-05-05 2008-02-01 Wyeth Corp Solid dosage formulations
EP2457563B1 (en) 2006-05-09 2017-03-22 Mallinckrodt LLC Zero-order modified release solid dosage forms
WO2008008434A1 (en) * 2006-07-11 2008-01-17 Mutual Pharmaceutical Company, Inc. Controlled-release formulations
KR20090042967A (ko) * 2006-08-14 2009-05-04 베링거 인겔하임 인터내셔날 게엠베하 플리반세린 제형 및 이의 제조방법
EP1925307A1 (en) * 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
JP5777273B2 (ja) 2008-07-10 2015-09-09 大正製薬株式会社 不快な呈味を有する薬物を含有する製剤粒子
US9005661B2 (en) 2009-09-15 2015-04-14 Beijing Team Hospital Management Co., Ltd. Osmotic pump controlled release tablet and preparation method thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110033506A1 (en) * 2008-02-08 2011-02-10 Adel Penhasi Combination dosage form of low-dose modafinil and low-dose sildenafil

Also Published As

Publication number Publication date
WO2012158030A3 (en) 2013-04-18
CA2835845A1 (en) 2012-11-22
ZA201309156B (en) 2015-02-25
CN109908099B (zh) 2021-10-29
PH12013502325A1 (en) 2014-02-10
JP2014513685A (ja) 2014-06-05
US20210290551A1 (en) 2021-09-23
WO2012158030A2 (en) 2012-11-22
IL229425B (en) 2020-05-31
US10966933B2 (en) 2021-04-06
JP6121990B2 (ja) 2017-04-26
BR112013029199B1 (pt) 2022-02-08
IL229425A0 (en) 2014-01-30
US20240165032A1 (en) 2024-05-23
CN109908099A (zh) 2019-06-21
BR112013029199A2 (pt) 2017-02-14
MX2013013204A (es) 2014-06-06
US20170354605A1 (en) 2017-12-14
KR20190083369A (ko) 2019-07-11
EA034288B1 (ru) 2020-01-24
MX353623B (es) 2018-01-22
CN103648487A (zh) 2014-03-19
CN103648487B (zh) 2019-04-19
AU2012256501B2 (en) 2017-04-06
BR112013029199A8 (pt) 2018-02-06
NZ618535A (en) 2016-03-31
EP2709597A2 (en) 2014-03-26
SG10201606751XA (en) 2016-10-28
SG194943A1 (en) 2013-12-30
NZ717187A (en) 2017-08-25
AU2012256501A1 (en) 2013-12-19
US20150056277A1 (en) 2015-02-26
KR20140048882A (ko) 2014-04-24
CA2835845C (en) 2020-07-28
EA201391689A1 (ru) 2014-05-30
US9763884B2 (en) 2017-09-19

Similar Documents

Publication Publication Date Title
KR102158948B1 (ko) 약물 전달 시스템
JP7627302B2 (ja) パルボシクリブの固形剤形
Ahmed et al. Formulation and evaluation of sustained release tablet of diltiazem hydrochloride
US8512747B2 (en) Pharmaceutical composition for the treatment of acute disorders
RU2678695C2 (ru) Композиции перорально распадающихся таблеток, содержащие кортикостероиды, для лечения эозинофильного эзофагита
TW202228721A (zh) 醫藥調配物
KR20190031444A (ko) 바깥 층 또는 부분에 존재하는 테스토스테론 화합물을 가진 약물 전달 시스템을 제조하기 위한 방법 및 이러한 약물 전달 시스템
US20250017932A1 (en) Methods of Administering Elagolix
Rashad et al. Chronological delivery of antihypertensive drugs in bilayered core-in-cup buccoadhesive tablets: In vitro and in vivo evaluation
NZ717187B2 (en) Drug delivery system
NZ618535B2 (en) Drug delivery system
RU2537169C1 (ru) Фармацевтическая композиция, содержащая дезлоратадин (варианты)

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6